Literature DB >> 29331672

Breast cancer screening: Where have we been and where are we going? A personal perspective based on history, data and experience.

Daniel B Kopans1.   

Abstract

It is important to understand the history of breast cancer screening to better understand the continuing effort to reduce access to screening. Since the randomized, controlled trials have shown a statistically significant mortality reduction for women ages 40-74, the appropriate threshold for initiating screening is age 40 with no data to support the use of the age of 50 as a threshold for screening. All women are at risk for developing breast cancer and all women should have access to screening.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Mammography; Screening

Mesh:

Year:  2017        PMID: 29331672     DOI: 10.1016/j.clinimag.2017.12.013

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  2 in total

Review 1.  Novel imaging approaches to screen for breast cancer: Recent advances and future prospects.

Authors:  Christopher L Vaughan
Journal:  Med Eng Phys       Date:  2019-10       Impact factor: 2.242

2.  Resveratrol promotes sensitization to Doxorubicin by inhibiting epithelial-mesenchymal transition and modulating SIRT1/β-catenin signaling pathway in breast cancer.

Authors:  Xiaoxia Jin; Yingze Wei; Yushan Liu; Xiaoyun Lu; Fei Ding; Jiatai Wang; Shuyun Yang
Journal:  Cancer Med       Date:  2019-01-29       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.